GHRH analog that stimulates natural growth hormone release, reduces visceral fat.
TL;DR — Tesamorelin is a growth hormone peptide with a typical starting dose of 2 mg. For a 10 mg vial, add 1 mL bacteriostatic water to yield 10 mg/mL.
Add 1 mL of bacteriostatic water to a 10 mg vial, injecting slowly down the inside wall. Swirl gently; never shake. This yields a concentration of 10 mg/mL.
What is the recommended dose of Tesamorelin?
A typical research dose is 2 mg. Consult the ASCEND calculator for your specific vial concentration and draw volume.
How many doses are in a Tesamorelin vial?
A 10 mg vial reconstituted with 1 mL BAC water yields approximately 5 doses at 2 mg each.
Peptide Intelligence
What is the half-life of Tesamorelin?
Tesamorelin has a short half-life of approximately 26 minutes after subcutaneous injection due to rapid DPP-IV cleavage. Despite this, its effects on GH release persist for several hours, and daily administration produces meaningful IGF-1 elevation and visceral fat reduction.
What is the FDA-approved indication for Tesamorelin?
Tesamorelin (Egrifta) is FDA-approved for the treatment of HIV-associated lipodystrophy, specifically excess visceral abdominal fat in HIV-infected patients on antiretroviral therapy. This is among the only FDA-approved GHRH analog applications.
Why must Tesamorelin be injected within hours of reconstitution?
Tesamorelin is highly unstable in solution due to peptide bond susceptibility to hydrolysis. Reconstituted Tesamorelin should be injected within 3 hours of preparation. Never pre-load syringes for later use. Stability decreases rapidly even under refrigeration.